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Introduction
Cantu syndrome (CS), which has also been referred to as hypertrichosis-osteochondrodysplasia-cardio-
megaly syndrome, is a rare multiorgan disease first recognized as such in 1982 (1). CS is characterized by 
congenital hypertrichosis, distinctive facial features, osteochondrodysplasia, and multiple cardiovascu-
lar abnormalities, including cardiomegaly, hypertrophy, pericardial effusion, pulmonary hypertension, 
and patent ductus arteriosus and cerebrovascular defects (2–5). Multiple reports have now confirmed 
that autosomal dominant gain-of-function (GOF) mutations in KCNJ8 and ABCC9, the genes encoding 
the Kir6.1 and SUR2 subunits of  ATP-sensitive potassium (KATP) channels, represent the genetic basis 
of  CS (6–11). The severity of  features varies widely between individuals, although genotype-phenotype 
correlations have been difficult to establish; interestingly, patients with the same mutation can span the 
clinical spectrum (6, 7, 12, 13).
Expressed in various tissues in the body, KATP channels are nucleotide-gated, potassium selective 
channels that couple cellular metabolism to electrical excitability. KCNJ8 and ABCC9 are adjacent genes 
on human chromosome 12p12.1. A paralogous pair of  genes (KCNJ11 [Kir6.2] and ABCC8 [SUR1]) is 
located on chromosome 11p15.1, with the result that multiple subunit combinations may exist in KATP 
Cantu syndrome (CS) is caused by gain-of-function (GOF) mutations in pore-forming (Kir6.1, 
KCNJ8) and accessory (SUR2, ABCC9) ATP-sensitive potassium (KATP) channel subunits, the most 
common mutations being SUR2[R1154Q] and SUR2[R1154W], carried by approximately 30% of 
patients. We used CRISPR/Cas9 genome engineering to introduce the equivalent of the human 
SUR2[R1154Q] mutation into the mouse ABCC9 gene. Along with minimal CS disease features, 
R1154Q cardiomyocytes and vascular smooth muscle showed much lower KATP current density 
and pinacidil activation than WT cells. Almost complete loss of SUR2-dependent protein and 
KATP in homozygous R1154Q ventricles revealed underlying diazoxide-sensitive SUR1-dependent 
KATP channel activity. Surprisingly, sequencing of SUR2 cDNA revealed 2 distinct transcripts, 
one encoding full-length SUR2 protein; and the other with an in-frame deletion of 93 bases 
(corresponding to 31 amino acids encoded by exon 28) that was present in approximately 40%  
and approximately 90% of transcripts from hetero- and homozygous R1154Q tissues, respectively. 
Recombinant expression of SUR2A protein lacking exon 28 resulted in nonfunctional channels. 
CS tissue from SUR2[R1154Q] mice and human induced pluripotent stem cell–derived (hiPSC-
derived) cardiomyocytes showed only full-length SUR2 transcripts, although further studies will 
be required in order to fully test whether SUR2[R1154Q] or other CS mutations might result in 
aberrant splicing and variable expressivity of disease features in human CS.
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channels in different tissues. KATP heterogeneity is further increased by the existence of  variably spliced 
SUR isoforms (14–16); particularly prominent are 2 major splice isoforms of  SUR2: SUR2A and SUR2B 
(17–19). KATP channels in vascular smooth muscle are predominantly composed of  Kir6.1 and SUR2B 
(20, 21), whereas SUR2A predominates in cardiac ventricular myocyte KATP channels (22, 23).
To date, more than 30 missense mutations (24) have been identified in CS patients, and all mutations 
that have been functionally characterized result in GOF of  KATP channels (7–11). In a previous study, we 
generated “CS mice,” in which the equivalent of  human SUR2[A478V] and Kir6.1[V65M] mutations were 
introduced into the relevant mouse loci. In each case, key cardiovascular features of  CS were replicated, 
and molecular, cellular, and systemic consequences increased from heterozygous (Het) to homozygous 
(Hom) conditions. Importantly, as the number of  genetically confirmed CS cases has risen, it has become 
clear that residue R1154 in SUR2 is particularly susceptible to mutation, with 24 of  72 patients (20 of  57 
unrelated families) carrying variants ABCC9[c.3461G>A], ABCC9[c.3460C>T], or ABCC9[c.3460C>G], 
which encode SUR2[p.R1154Q], SUR2[p.R1154W], and SUR2[p.R1154G], respectively (24). While this 
may reflect a susceptible genomic structure, at least the R1154Q mutation results in more severe GOF than 
many other CS mutations (7, 11), which raises the possibility that excessive occurrence of  such mutations 
in patients reflects greater penetrance relative to other mutations. To gain further insight into the disease 
consequences of  the R1154Q mutation, we used CRISPR/Cas9 genome engineering to generate CS mice 
carrying the SUR2[R1151Q] mutation, equivalent to human R1154Q. We show that the cardiovascular 
abnormalities in these CS mice were much less severe than in either of  the 2 previously studied animal 
models, but this was accompanied by a marked decrease in SUR2-dependent KATP density, in both cardiac 
and smooth muscle cells. Further experiments showed that this was the result of  the unanticipated appear-
ance of  ABCC9 mRNA splicing, which led to in-frame exon deletion and loss of  functional protein.
Results
The human R1154Q substitution causes KATP GOF, but only a mild CS phenotype. CRISPR/Cas9 gene edit-
ing was used to introduce a single nucleotide mutation (ABCC9[c.3452G>A]; SUR2[p.R1151Q]) in the 
endogenous mouse ABCC9 locus, resulting in protein substitution analogous to the most common human 
CS mutation, SUR2[R1154Q]. Both heterozygous (SUR2WT/RQ) and homozygous (SUR2RQ/RQ) mice were 
viable and fertile. We subsequently analyzed cellular, organ, and whole animal phenotypes of  these ani-
mals, which we refer here to as SUR2[R1154Q] mice to distinguish it from human CS.
One of  the most consistent features of  patients with CS is pronounced cardiomegaly (24, 25). Con-
sistent with this, hearts were larger in heterozygous SUR2WT/RQ than WT mice, but not obviously more 
so in homozygous SUR2RQ/RQ mice (Figure 1, A and B). Therefore, R1154Q hearts displayed chamber 
dilation and cardiac enlargement similar to, although much less dramatic than, that seen previously in 
A478V or V65M CS mouse hearts (26). Isolated aortic diameter was greater in SUR2WT/RQ than WT mice 
at all pressures (Figure 1C) although, again, there was no further increase in SUR2RQ/RQ mice, and carotid 
artery dimensions were not different between WT and R1154Q animals (Figure 1D). Slope compliance 
(reflecting noncontractile biomechanical properties) was not obviously different between genotypes (Fig-
ure 1C). As shown in Figure 2A, both SUR2WT/RQ and SUR2RQ/RQ mice maintained diurnal fluctuation in 
blood pressure, but unlike in SUR2[A478V]-expressing mice (26), blood pressures were not significantly 
lower than control in either SUR2WT/RQ or SUR2RQ/RQ mice (Figure 2A). Moreover, while pinacidil had 
similar BP-lowering effect in control and Het SUR2WT/RQ mice, it had almost no effect on BP in SUR2RQ/RQ 
mice (Figure 2C). In contrast, pinacidil raised heart rates (HRs) similarly in all genotypes (Figure 2D). 
Unexpected KATP channel properties in R1154Q cardiac and vascular smooth muscle cells. Mice expressing 
introduced SUR2[A478V] and Kir6.1[V65M] CS GOF mutations exhibit marked lowering of  blood pres-
sure and cardiac enlargement (26). Since previous studies show that recombinant SUR2[R1154Q] causes 
a significant GOF — in both human SUR2 (7) and rat SUR2 with the identical DNA mutation (11) — the 
above results (i.e., limited or no increase in vessel diameters and compliance, lack of  effect on BP, and lack 
of  pinacidil action in SUR2RQ/RQ) are unexpected, and raise questions regarding the level and nature of  
KATP channels in these mutant tissues. We therefore examined the density of  KATP channels, and sensitiv-
ity to the KATP channel openers pinacidil (acting primarily on SUR2) and diazoxide (acting primarily on 
SUR1) in excised membrane patches from ventricular myocytes (Figure 3A). Overall KATP channel den-
sity was much lower than WT in SUR2WT/RQ myocytes, and dramatically so in homozygous SUR2RQ/RQ 
myocytes (Figure 3B). Moreover, in striking contrast to the findings in recombinant R1154Q channels, 
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pinacidil-mediated activation was essentially absent in homozygous SUR2RQ/RQ cardiomyocytes, while 
relative diazoxide-mediated activation was markedly enhanced (Figure 3C).
This unexpected lowering of  channel density and apparent switch in pharmacological sensitivity 
from pinacidil to diazoxide suggests that levels of  SUR2-dependent channel complexes are reduced in 
R1154Q hearts, almost completely in homozygous SUR2RQ/RQ hearts, and that the remaining functional 
sarcolemmal channels are predominantly SUR1 dependent. To test the latter suggestion directly, we 
additionally generated SUR2RQ/RQ mice on a SUR1–/– background (27); in this case, no KATP was detect-
ed (Figure 3B), indicating that channels in SUR2RQ/RQ animals are essentially SUR1 dependent. We 
further examined underlying KATP subunit levels in isolated ventricular tissue by Western blot analysis 
(Figure 3D). This revealed a marked decrease in core- and complex-glycosylated SUR2A proteins in 
homozygous SUR2RQ/RQ hearts compared with littermate control hearts (Figure 3D). In contrast, levels 
of  core-glycosylated SUR1 protein were increased in SUR2RQ/RQ hearts (Figure 3D). Both SUR1 and 
SUR2A in WT hearts are normally associated with Kir6.2 (28), but only core-glycosylated, approximate-
ly 140 kDa forms of  both SUR1 and SUR2A were present in Kir6.2–/– hearts (Figure 4A), demonstrat-
ing that they both require association specifically with Kir6.2 to mature. As shown in Figure 4B, treat-
ment with peptide:N-glycosidase F (PNGase F) resulted in complete deglycosylation of  both SUR1 and 
SUR2A, demonstrating that total SUR1 was indeed increased in SUR2RQ/RQ hearts, although the excess 
was incompletely glycosylated. The results confirm that, consistent with loss of  SUR2A-dependent KATP 
current and relative increase in SUR1-dependent channels, mature SUR2A protein levels were reduced, 
while total SUR1 protein was increased, in SUR2RQ/RQ hearts.
The effects of  the introduced mutation on KATP channel function were also examined in vascular 
smooth muscle cells (VSMCs). In contrast to the findings in A478V and V65M animals (26), whole-cell 
patch clamp recordings using an intracellular pipette solution containing no ATP (see Methods) revealed 
no elevation of  basal KATP conductance in acutely isolated aortic smooth muscle cells from SUR2
WT/RQ 
compared with WT mice, and significantly lower conductance in SUR2RQ/RQ compared with WT cells 
(Figure 5, A and B). Application of  pinacidil provoked a significant increase in conductance in WT 
VSMCs, but there was less of  an effect in SUR2RQ/RQ and very little effect in VSMCs from SUR2RQ/RQ 
mice (Figure 5, A and B). These results indicate that KATP density was also markedly reduced in R1154Q 
Figure 1. Cardiovascular phenotype of R1154Q mice. (A and B) Cardiomegaly in heterozygous SUR2WT/RQ (WT/RQ) and homo-
zygous SUR2RQ/RQ (RQ/RQ) hearts. (C and D) Isolated ascending aortas of WT/RQ and RQ/RQ hearts show similar increases in 
diameter at all pressures relative to WT (C), but carotid artery mechanical properties are not different from those of WT (D) (n 
= 5 for WT, n = 7 for WT/RQ, n = 6 for RQ/RQ). Statistical significance was determined by 2-way ANOVA followed by post hoc 
Tukey’s test correction for multiple comparisons;*P < 0.05, **P < 0.01 compared with WT. HW, heart weight; TL, tibia length.
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smooth muscle, although SUR2RQ/RQ VSMCs were hyperpolarized relative to WT VSMCs following 
break-in in current clamp mode (Figure 5, C and D), indicating at least some net KATP GOF under intact 
cell physiological conditions in SUR2RQ/RQ VSMCs.
Taken together, the data indicate that, while the expected molecular consequence of  the SUR2[R1154Q] 
substitution is a significant GOF of  SUR2-dependent KATP channels in blood vessels and the heart, there 
were minimal cardiovascular CS features. There was an unexpected downregulation of  SUR2-dependent 
KATP channel density in heterozygous SUR2
WT/RQ cardiac and vascular smooth muscle myocytes — dra-
matically so in homozygous SUR2RQ/RQ tissues — accompanied by an increase in SUR1 levels in the heart.
Unanticipated alternate splicing of  SUR2 exon 28 in R1154Q tissues. The above results led us to conclude 
that although the R1154Q mutation indeed causes a GOF in KATP channel properties (since smooth mus-
cle is still relatively hyperpolarized), the expressivity of  CS features is severely blunted in these animals 
by the unexpected reduction in SUR2-dependent KATP density that is not seen in other (A478V, V65M) 
CS mice (26). In homozygous SUR2RQ/RQ mice there was almost complete disappearance of  SUR2- 
dependent KATP channels in both heart and blood vessels, and a consequent reduction in disease severity, 
as reflected by lack of  obvious effects on BP and reduced effects on heart size (Figures 1 and 2). We con-
sidered the possibility that CRISPR-generated mistakes may have led to additional mutations that result-
ed in defective protein, but sequencing of  gDNA more than 5000 bp on either side of  the introduced 
mutation failed to detect any additional mutations (data not shown). It has long been recognized that 
there are multiply spliced forms of  the SUR2 protein (15, 29–31), the best characterized being the SUR2A 
and SUR2B isoforms, which result from alternate splicing of  the terminal exon 38A/B. The R1154Q and 
R1154W mutations are in exon 27, and while there is to our knowledge no evidence in the literature for 
alternate splicing of  this region of  the gene, the specific location of  the underlying mutations (13 and 14 
bases, respectively, before the end of  exon 27; Figure 6, A–C) places them in a potential exon splicing 
enhancer (ESE) region that may influence exon splicing (32). We isolated mRNA from WT and R1154Q 
mouse hearts, generated cDNA corresponding to SUR2A and SUR2B, and sequenced the entire coding 
region. The introduced c.3452G>A mutation was present in fewer than 50% of  heterozygous SUR2WT/RQ 
and close to 100% of  homozygous SUR2RQ/RQ transcripts, but, strikingly, heterozygous cDNA reads 
became doubled sequences immediately following the last nucleotide of  exon 27 (Figure 6B). Close 
inspection revealed that this corresponds to approximately half  of  the reads in heterozygous SUR2WT/RQ, 
and essentially all reads in homozygous SUR2RQ/RQ, transcripts, reflecting an exact in-frame deletion of  
the 93 bases in the following exon, exon 28 (Figure 6B).
Figure 2. Cardiovascular function of R1154Q mice. (A) Mean arterial pressure (MAP) and (B) mean HR in conscious WT, 
heterozygous SUR2WT/RQ, and SUR2RQ/RQ mice during day and night. (C) MAP and (D) HR in anesthetized mice showing 
blunted response to the KATP channel activator pinacidil (Pin) in SUR2
RQ/RQ mice. Statistical significance was determined 
by 1-way ANOVA followed by Tukey’s test for pairwise comparison; asterisks indicates significant difference (P < 0.05) 
within genotypes.
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It might be hypothesized that this exon 28 splicing of  SUR2 mRNA could be a cellular regulato-
ry mechanism to moderate abnormally increased KATP channel function activity. However, this does 
not seem likely, since no alternative splicing of  exon 28 was detected in heterozygous or homozygous 
SUR2[A478V] or Kir6.1[V65M] hearts (data not shown), or in WT hearts (Figure 6B). Instead, the tight 
dependence of  splicing on the presence of  the c.3452G>A mutation indicates that the nucleotide change 
itself  is directly responsible for the splicing event.
To assess the effect of  deleting exon 28 on KATP channel activity, we engineered SUR2A cDNA 
with exon 28 deleted. When coexpressed with WT Kir6.2, SUR2A[R1154Q,Δexon28] failed to gener-
ate significant KATP channel activity in heterologous expression (Figure 7, A and B). In subunit mixing 
experiments, with equal transfection of  WT SUR2A and SUR2A[R1154Q,Δexon28] cDNA, there was 
no evidence for dominant-negative suppression of  heterologously expressed KATP channels by exon- 
deleted subunits (Figure 7C). The data were best fit under the assumption that even 1 full-length WT sub-
unit would be sufficient to rescue function (Figure 7C), consistent with truncated subunits being rapidly 
degraded and not incorporated into KATP complexes.
Lack of  splicing in human R1154Q mutant tissues or induced pluripotent stem cell–derived cells. The intro-
duced mutation thus results in alternate splicing and consequent loss of  SUR2 protein in CS mice. In turn, 
this leads to significantly blunted phenotype severity, despite the R1154Q mutation showing a marked 
Figure 3. Decreased KATP channel density and switch to SUR1 dependence in SUR2A[R1154Q] hearts. (A) Representative 
inside-out patch clamp recordings of KATP channel activity from acutely dissociated ventricular myocytes from WT and 
SUR2RQ/RQ mice. Inhibition by 10 or 0.1 μM MgATP and the response to the K channel openers pinacidil and diazoxide 
(Diaz) at 100 μM, in the presence of MgATP (recording at –50 mV membrane potential), are shown. (B) Absolute KATP 
current level in zero ATP, from experiments as in A. (C) KATP current, as a fraction of current in zero ATP, from experiments 
as in A. (D) Western blot analysis of the membrane fraction from ventricular heart tissue of WT and SUR2RQ/RQ mice (4 
biological replicates each) showing protein steady-state levels of KATP channel subunits and Na/K-ATPase α subunits. 
Since both SUR subunits are only core-glycosylated when the Kir6.2 subunit is missing (28), tissue from a single Kir6.2–/– 
mouse is also shown for reference. Statistical significance was determined by 1-way ANOVA followed by Tukey’s test for 
pairwise comparison; * P < 0.05, ** P < 0.01, *** P < 0.001.
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molecular GOF (11).If  the same splicing is similarly present in humans, it would tend to mitigate the 
effects of  the mutation. In addition, variable SUR2 splicing between individuals could potentially account 
for the quite variable expressivity in CS individuals with the R1154Q mutation (24). We further exam-
ined the tissue dependence of  exon 28 skipping in cDNAs generated from mRNA isolated from multiple 
R1154Q mouse tissues. As shown in Figure 7D, the apparent fraction of  spliced transcripts was similar 
in skeletal, smooth, and cardiac muscle, being approximately 25%–35% in heterozygous, SUR2WT/RQ and 
approximately 75%–100% in homozygous, SUR2RQ/RQ animals. This further indicates that alternate SUR2 
splicing is driven by the nucleotide change via a cell-autonomous mechanism, independent of  tissue type. 
The less-than-stoichiometric ratio of  spliced to unspliced transcript in the heterozygous case further sug-
gests slower transcription or reduced stability of  the mutant mRNA. We obtained a skin and skeletal mus-
cle biopsy sample from a single R1154Q patient and successfully isolated ABCC9 mRNA. However, PCR 
from both samples revealed only single product bands corresponding to full-length SUR2A cDNA and no 
band corresponding to exon 28–deleted cDNA (Figure 7E).
We also obtained PBMCs from a patient with the R1154Q mutation, and renal epithelial cells (RECs) 
were obtained from a patient with the R1154W mutation. Human induced pluripotent stem cells (hiPSCs) 
were generated from these primary cells using Sendai virus–based reprogramming vectors. Two subclonal 
hiPSC lines were produced for each mutation, and DNA sequencing analysis confirmed the expected muta-
tion in each CS hiPSC line. A GCaMP6-expressing hiPSC line from an unaffected individual was used as 
a control. Expression of  human pluripotency-associated genes and a normal karyotype were confirmed for 
all hiPSCs prior to subsequent experiments. WT and CS hiPSCs were differentiated into cardiomyocytes as 
previously described (33). When we used this approach, hiPSC-derived cardiomyocytes exhibiting robust 
rhythmic contractile behavior were present by days 7–9. Subsequently, a 10-day lactate purification step 
was used to metabolically select for cells (Figure 7F) with cardiomyocyte-specific biochemical properties 
enabling survival exclusively via lactate metabolism, as previously described (34). For unknown reasons, 
we were unable to detect KATP channels in these myocytes (data not shown). However, RT-PCR analysis 
Figure 4. SUR1 and SUR2A maturation in SUR2A[R1154Q] hearts. (A) Western blot analysis of the membrane fraction 
from ventricular heart tissue of WT and Kir6.2–/– mice. Representative result from 3 biological replicates. (B) PNGase F 
treatment (18.75 U/μL) of ventricular heart membrane lysates of WT, SUR2WT/RQ, SUR2RQ/RQ, and Kir6.2–/– mice. Repre-
sentative Western blot of 2 biological replicates.
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of  RNA isolated from WT, R1154Q, and R1154W hiPSC–derived cardiomyocytes on day 45 revealed full-
length SUR2A transcripts in each genotype, with no evidence of  detectable alternate splicing (Figure 7F). 
Although the amino acid sequence in this region of  SUR2 is identical in mice and humans (Figure 6C), there 
are slight variations in codon usage between the 2 species (Figure 6A) that could affect ABCC9 mRNA splic-
ing. Nevertheless, the lack of  detectable alternate splicing in human R1154Q and R1154W iPSC–derived 
cardiomyocytes suggests that the disease mutation may not lead to alternate splicing in native human tissues.
Discussion
The cellular pathology of  KATP GOF in Cantu syndrome: additional outcome twists with R1154Q. The present study 
demonstrates that, when introduced into the mouse genome, the most common CS-associated ABCC9 muta-
tion (encoding human SUR2[R1154Q]) resulted in qualitatively the same cardiovascular features as the 
SUR2[A478V] and Kir6.1[V65M] mutations (26), providing further confirmation of  the common cardio-
vascular outcome of  vascular dilation and cardiac enlargement resulting from SUR2- or Kir6.1-dependent 
KATP GOF in CS. However, in SUR2[R1154Q] animals, the disease was quantitatively much less severe than 
naively predicted based on the molecular severity of  the mutation. The reason for the reduced severity of  
outcome was shown to be a reduction in overall KATP density in both vascular smooth muscle and heart, par-
ticularly in the case of  homozygous SUR2RQ/RQ mice. This in turn was shown to be a result of  the genomic 
c.3452G>A mutation causing altered pre-mRNA splicing, with deletion of  the following exon 28 and gen-
eration of  nonfunctional SUR2 proteins, and downregulation of  overall KATP density. SUR2A levels were 
strongly reduced in homozygous SUR2RQ/RQ mice, with the SUR2A protein that was present showing lower 
complex glycosylation, indicative of  ER localization, as seen in Kir6.2-knockout animals (28).
In general, genetic or pharmacological manipulations that alter the levels of  any KATP subunits, even 
complete knockout of  any given subunit, have not been shown to result in marked compensatory changes 
in other subunits, in any tissues (35–37). In the present case, there was a surprising increase in relative 
diazoxide sensitivity of  cardiac KATP, accompanied by a small increase in absolute levels of  diazoxide-sen-
sitive current, and of  mature, glycosylated SUR1 protein, in the heart. Previous studies have suggested that 
SUR1, while present in the heart, loses out to SUR2A in competition for association with Kir6 subunits, 
resulting in low levels of  fully mature, glycosylated SUR1 being present in KATP channels at the membrane 
surface (28). We speculate this may be because SUR2A-containing channels normally leave the secretory 
Figure 5. Loss of pinacidil-sensitive SUR2-dependent KATP channels in SUR2A[R1154Q] vascular smooth muscle. (A) Rep-
resentative whole-cell voltage clamp recordings from acutely isolated aortic smooth muscle cells from WT and SUR2RQ/RQ  
mice. Cells were voltage clamped at –70 mV. Glib, glibenclamide. (B) Summary of whole-cell current densities from voltage 
clamp recordings as in A, showing significantly reduced pinacidil-activated KATP conductance in SUR2RQ/RQ cells. Statistical 
significance was determined by multi-way ANOVA, followed by 2-tailed t test pairwise comparison with Bonferroni’s correc-
tion for multiple comparisons (adjusted α = 0.008); *P < 0.008. (C) Representative whole cell current-clamp recordings from 
acutely isolated aortic smooth muscle cells from WT and homozygous SUR2RQ/RQ mice using an intracellular pipette solution 
absent of nucleotides. (D) Summary of initial (init) and final (fin) membrane potentials from experiments as in C. Statistical 
significance was determined by 1-way ANOVA followed by Tukey’s tests; ** P < 0.01.
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pathway more efficiently, so that when mutant SUR2A protein is depleted, SUR1 accesses Kir6.2, which 
explains the higher levels of  core-glycosylated SUR1 and diazoxide-activatable current in R1154Q hearts.
Cardiac hypertrophy and enhanced cardiac output are a consistent finding in CS patients (25) and in both 
Kir6.1[V65M] and SUR2[A478V] mutant mice (26). As we have shown in these mice, cardiac hypertrophy 
arises independently of  ventricular KATP activity, as a secondary consequence of  enhanced vascular KATP activ-
ity, resulting in vasodilation; reduced vascular resistance; and, in response, enhancement of  renin-angiotensin 
signaling, adrenergic signaling, or other vasoresponsive pathways (26, 38). We also saw cardiac enlargement in 
SUR2[R1154Q] mutant mice, but this was less marked than in V65M or A478V mice, consistent with reduced 
overall expression of  SUR2-dependent KATP channel levels in the vasculature (as well as the heart). Cardiac 
β-adrenergic receptor (β-AR) activation promotes cardiac hypertrophy (39) and, as we have also shown, can 
enhance trafficking of  SUR1-dependent KATP channels to the myocardial surface membrane (28). This in turn 
could contribute to increased SUR1-containing channels at the cell surface in R1154Q hearts.
Variable disease-causing/modifying consequences of  alternate splicing in ABCC genes. Strikingly, the 
SUR2[R1154Q] (ABCC9 c.3461G>A) mutation induced alternate splicing of  SUR2 mRNA, generating a 
truncated SUR2 protein that lacks the 30 amino acids of  exon 28. When expressed together with Kir6.2 in 
recombinant cells, the SUR2[R1154Q,Δexon28] construct failed to generate active KATP channels. In mixed 
expression with full-length SUR2A cDNA, there was no evidence for a dominant-negative effect of  the 
SUR2[R1154Q,Δexon28] construct; the data were best fit by assuming that even 1 full-length subunit was 
sufficient to rescue function. This can explain the observed reduction in overall channel density yet per-
sistence of  vascular hyperpolarization and cardiac enlargement in R1154Q animals; in the case of  hetero-
zygous mice, the disease features were less marked than seen in heterozygous SUR2[A478V] animals (26, 
38), even though the molecular consequence of  the mutation itself  was more severe (7, 11). In contrast to 
Figure 6. Abnormal splicing in SUR2A[R1154Q] mRNA. (A) Canonical cDNA sequence for human and mouse SUR2 over the exon 27–29 region (non-iden-
tities indicated by gray). Human nucleotide c.3461 (mouse c.3452) G>A mutation generating p.R1154Q is indicated by the red box. (B) Analysis of cDNA 
PCR product by gel electrophoresis and by direct sequencing of the selected bands reveals an exact deletion corresponding to the 93 nucleotides of exon 
28 in approximately half of heterozygous WT/RQ and almost all homozygous RQ/RQ mouse transcripts (red arrowheads). (C) Top: Amino acid sequence 
of residues 1149–1194 (human) is identical in human and mouse SUR2. Bottom: Model of the Kir6/SUR complex (Protein Data Bank 5WUA) indicates the 
predicted location of the R1154Q mutation and amino acids encoded by exon 28.
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SUR2[A478V] animals, the disease features of  homozygous SUR2[R1154Q] animals were no more dra-
matic than those of  the heterozygous animals, and KATP channel activities were more markedly decreased, 
particularly in smooth muscle — explained by the enhanced degree of  splicing.
In many genes, exon inclusion/skipping is becoming recognized as a more common consequence of  
disease mutations than previously assumed (40–42). Multiple intra-intronic and intra-exonic mutations in 
CFTR (ABCC7), a gene closely related to ABCC8, have been associated with nonfunctional protein and 
cystic fibrosis (CF) disease (43). In one systematic study involving both in silico predictions and analysis of  
exon skipping in recombinant minigenes (44), 9 of  19 disease-associated CFTR mutations induced exon 
skipping in a fraction of  transcripts, but did not abolish WT expression completely, potentially underlying 
variably milder phenotypes. Mutations occurring at conserved intron–exon boundaries (i.e., splicing junc-
tions at the −1, −2, −3, and +1, +2, +3 positions) are expected to affect splicing of  the immediately adja-
cent exons. The consequence of  such mutations, for example, c.1117-1G>A and c.1209+1G>A in ABCC7, 
are generally considered to be severe, whereas mutations occurring at more distant positions, for example, 
+5, +6, or −5 and −6, are mild, typically associated with only mild CF disease (45).
Alternate splicing is well recognized as a component of  ABCC9 regulation; the canonical finding is that 
cardiomyocytes express SUR2A, a variant containing exon 38A, whereas smooth muscle cells typically 
express SUR2B, containing the alternate C-terminal exon 38B. Previous studies in mice have also identi-
fied multiple additional potential spliced SUR2 variants (14, 15, 19), including short forms of  only 28 and 
68 kDa (29), in addition to the full-length (~150 kDa) form in the WT cardiac sarcolemmal membrane. 
Some small exon deletions modulate channel ATP sensitivity (15), whereas coimmunoprecipitation of  
short forms lacking NBD1 but containing NBD2 with Kir6.1 or Kir6.2 suggests that abnormal channel 
properties could be generated (29). Other studies identified an additional 55 kDa form of  the protein lack-
ing exons 5–28 in mitochondria (termed mitoSUR2) generated by a nonconventional intraexonic splicing 
Figure 7. Functional consequence of SUR2[R1154Q] mRNA splicing. (A) Representative Rb efflux experiments from 
untransfected COSm6 cells (Unt) and cells transfected with WT, R1154Q (RQ), and R1154Q[Δexon28] SUR2A, plus Kir6.2. 
(B) Fractional efflux at 40 minutes, from experiments as in A. Statistical significance was determined by 1-way ANOVA 
followed by Tukey’s tests; ***P < 0.001. (C) Fractional efflux at 40 minutes, from experiments similar to those in A, in 
cells transfected with SUR2[R1154Q,Δexon28] subunits in addition to SUR2[R1154Q] (plus Kir6.2) subunits. Dashed lines 
are predicted levels of efflux assuming that 1, 2, 3, or 4 WT subunits in a randomly assembling complex are necessary 
to restore function. (D) cDNA PCR product analyzed by gel electrophoresis reveals similar levels of splicing in R1154Q 
ventricle, smooth muscle, and skeletal muscles, suggesting that SUR2 function will be significantly reduced in all tissues. 
(E) cDNA PCR product from human R1154Q patient skeletal muscle and skin analyzed by gel electrophoresis reveals only a 
single band corresponding to a 642 bp fragment from full-length SUR2A cDNA and no band corresponding to the predicted 
549 bp from exon 28–deleted cDNA (red arrowheads). (F) Image of R1154Q patient iPSC–derived cardiomyocytes (scale bar: 
50 μm). cDNA PCR product from R1154Q or R1154W patient iPSC–derived cardiomyocytes analyzed by gel electrophoresis 
reveals only a single band corresponding to the 325 bp fragment from full-length SUR2A cDNA and no band corresponding 
to the predicted 232 bp fragment from exon 28–deleted cDNA (red arrowheads) (representative result from n= 3 repeats).
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(IES) event within the 4th and 29th exons of  SUR2 mRNA (46). Specific deletion of  exon 5 of  ABCC9, to 
ablate expression of  both plasma membrane and the mitoSUR2 short form, resulted in neonatal cardio-
myopathy, potentially due to failure of  the heart to transition normally from fetal to mature myocardial 
metabolism (47). Conversely, mice overexpressing the 55 kDa short-form protein had improved recovery 
from ischemia/reperfusion injury relative to WT hearts (48).
Such studies indicate that exon splicing could result in distinct forms of  the protein that are expressed 
in different cellular compartments, with profoundly different effects on cell function. The present data raise 
the possibility that R1154Q (or R1154W, and perhaps other) CS mutations might result not only in a func-
tional KATP GOF but, by causing exon skipping, but also in a truncated protein and hence an effective mixed 
loss/GOF phenotype, potentially explaining the variable expressivity of  disease features in human CS (24). 
In cardiomyocytes derived from R1154Q CS patient iPSCs, we failed to detect any exon 28 skipping. The 
amino acid sequence in the region of  R1154 is identical in mouse and human, but there is some variation 
in codon usage between the 2 species, and, although splicing prediction algorithms suggest that the human 
mutation and the CRISPR-introduced mouse mutation should alter exon splicing similarly, it is possible 
that the mouse sequence is more susceptible. It is also possible, given the unnatural differentiation process 
for iPSC-derived cells in vitro, that different outcomes might be obtained in native tissues, and additional 
studies will be necessary to confirm whether or not such splicing occurs in R1154 mutant human CS. Nev-
ertheless, the finding that R1154Q induces such splicing in any genome illustrates the principle that SUR2 
GOF mutations can also be associated with additional LOF resulting from variable splicing that leads to 
reduced protein levels, such that the net effect could be either GOF or LOF in different tissues. We have 
demonstrated that isolated SUR2 LOF results in a very distinct constellation of  features in ABCC9-related 
intellectual myopathy syndrome (AIMS) (49). Hence, dual GOF/LOF consequences of  CS mutations could 
result in not just quantitatively, but qualitatively variable outcomes and marked variability of  CS pathologies, 
and hence might underlie the marked variation in severity of  CS consequences that is seen in patients (24).
Conclusions. Recent studies have defined the genetic basis of  CS — first recognized as a distinct syn-
drome 30 years ago — as GOF in KATP channel genes, and have further defined the consequent mechanistic 
basis of  multiple CS features. The most common human CS mutations, SUR2[R1154Q] and [R1154W], 
are present in approximately 30% of  patients with CS. In the present study, we have shown that when intro-
duced into the mouse locus, the SUR2[R1154Q] equivalent mutation caused canonical features of  CS, but 
also the unanticipated consequence of  alternate mRNA splicing, which resulted in a decrease in functional 
SUR2 protein levels. This is effectively a LOF that counteracts the mutational GOF action and leads to 
lower CS phenotypic severity. While studies in cells from SUR2 R1154Q and R1154W patient cells failed 
to reveal a similar outcome, the possibility remains that these or other GOF CS mutations might result in a 
counteracting loss of  functional protein levels by a similar mechanism, which could then help explain, and 
have significant implications for, the wide variability of  CS disease expressivity.
Methods
CRISPR/Cas9 genome editing
Using CRISPR/Cas9-mediated genome engineering technology (50), we generated knockin mice carrying a 
human GOF mutation in the ABCC9 gene, which encodes the accessory SUR2 subunit of  the KATP channel. 
Guide RNA (gRNA) target sequences predicted using the MIT CRISPR design tool (http://crispr.mit.edu) 
were cloned into plasmid pX330 (Addgene 42230). sgRNA activity was validated in vitro by transfection 
of  N2A cells using Roche X-tremeGENE HP (MilliporeSigma), followed by T7E1 assay (New England 
BioLabs Inc.). The T7 sgRNA template and T7 Cas9 template were prepared by PCR amplification and gel 
purification, followed by RNA in vitro transcription with the MEGAshortscript T7 kit (gRNA) or the T7 
mMessage mMachine Ultra kit (Cas9). After transcription, RNA was purified with the Megaclear kit (Life 
Technologies). 200 nt ssODN donor DNAs with the appropriate mutation centered within the oligonucle-
otide were synthesized by Integrated DNA Technologies as ultramer oligonucleotides.
B6CBA F1/J female mice (3–4 weeks old; The Jackson Laboratory) were superovulated and mated over-
night with B6CBA F1/J male mice (>7 weeks old). Zygotes were harvested from the ampullae of superovu-
lated females and placed in potassium-supplemented simplex optimized medium (KSOM; MR106D) before 
microinjection. Microinjection of the Cas9, sgRNA, and ssDNA template (at a final concentration of 50 
ng/μL Cas9 WT RNA, 25 ng/μL gRNA, and 20 ng/μL ssODN DNA) was performed in flushing holding 
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medium (FHM; EmbryoMax, MR-024-D, MilliporeSigma). After injection, zygotes were incubated at 5.5% 
CO2 at 37°C for 2 hours, and surviving embryos were transferred to ICR recipient mice (The Jackson Labora-
tory) by oviduct transfer. Founders were identified using a QIAGEN pyrosequencer and Pyromark Q96 2.5.7 
software. We identified multiple viable and fertile positive founder mice carrying the SUR2[R1151Q] mutation 
(equivalent to human SUR2[R1154Q]), and we refer to these as SUR2[R1154Q] mice for direct comparison 
to the human CS equivalent. Successful mutation was verified in founder (F0) mice by Sanger sequencing of  
gDNA. Mutant mice were subsequently crossed with C57BL/6J mice (The Jackson Laboratory) to generate 
heterozygous F1 SUR2
WT/RQ lines. PCR was used to generate amplicons of ABCC9 spanning more than 5 kb on 
either side of the introduced mutation, from gDNA isolated from mouse tails, and resultant PCR products were 
sequenced to confirm the absence of additional, unintended mutations. After verification, 1 F1 animal from 1 
line of each genotype was selected and subsequently bred with C57BL/6J mice for multiple (>6) generations 
to generate the hetero- and homogeneous R1154Q as well as WT littermates that were used in experiments.
Generation of human iPSCs and analysis of derived cardiomyocytes
R1154W patient RECs were reprogrammed to hiPSCs by the Washington University School of  Medicine 
in St. Louis Genome Engineering and iPSC Core (GEiC) using Sendai virus–based reprogramming vectors. 
After 4 unsuccessful attempts to reprogram R1154Q patient RECs, PBMCs were provided by the patient, 
and were successfully reprogrammed by the GEiC using the Sendai virus–based reprogramming cocktail. 
hiPSCs were maintained on a 4-day passaging cycle. Differentiation to cardiomyocytes was carried out in 
entirely chemically defined conditions via temporal modulation of  canonical Wnt signaling (33).
RNA extraction and analysis
RNA was isolated from freshly dissecting cardiac apices or from iPSC-derived cardiomyocyte cultures 
using TRIzol (Thermo Fisher Scientific), and first-strand cDNA was synthesized using SuperScript III 
First-Strand Synthesis System (Thermo Fisher Scientific).
Protein analysis
Protein extraction from heart tissue. Snap-frozen tissue was thawed on ice and equilibrated with ice-cold homog-
enization buffer (protease inhibitors, 50 mM NaCl, 0.32 M sucrose, 2 mM EDTA, 20 mM HEPES pH 7.4). 
Atria were dissected from ventricles. The ventricular tissue was diced, resuspended in homogenization 
buffer, and homogenized via a Miccra D-1 homogenizer and subsequent strokes by a manual glass-Teflon 
Dounce homogenizer. The suspension was then centrifuged at 100,000g. The obtained membrane pellet 
was resuspended in homogenization buffer, aliquoted, and snap frozen with liquid nitrogen. Membranes 
were resuspended in solubilization buffer (1.5% Triton X-100, 0.75% sodium deoxycholate, 0.1% SDS, pro-
tease inhibitors in 10 mM NaCl, 5 mM EDTA, 2.5 mM EGTA, 50 mM Tris-HCl pH 7.35) and centrifuged 
at 50,000g at 4°C. Supernatant was subjected to TCA to a final concentration of  12.5 % and incubated for 
30 minutes on ice. The pellet was acetone washed twice and air dried at 37°C; supplemented with 1× SDS 
sample buffer (50 mM Tris-HCl pH 6.8, 2% SDS, 0.1% bromophenol blue, 10% glycerol) containing 100 
mM DTT; and resuspended for subsequent analysis by SDS-PAGE.
Glycosidase treatment. 40 μL glycoprotein denaturing buffer (reconstituted with 1× glycoprotein 
denaturing buffer, 2.5% NP-40, 1× G7 in ddH20) was added to TCA-precipitated air-dried pellets from 
approximately 100 μg total protein and agitated at room temperature for 30 minutes. Subsequently, 1.5 
μL of  the glycosidase (PNGase F, 750 U; New England BioLabs Inc.) was added to the mixture. After 
incubation at 37°C for 1 hour at 1000 rpm, the mixture was supplemented with 5× SDS sample buffer 
and 100 mM DTT, agitated for 30 minutes, and analyzed by SDS-PAGE.
Protein analysis by Western blotting. For separating proteins via SDS-PAGE, 6% polyacrylamide gels 
were used for proteins greater than 100 kDa and 12% for other proteins. Electrophoresis was performed 
at constant current, limited to 15 mA per gel. Gels with separated proteins were put onto a nitrocellulose 
membrane and placed between 2 blotting papers, and electroblotted for 90 minutes in transfer buffer (25 
mM Tris, 192 mM glycine, pH 8.3) at 4°C with a constant voltage of  60 V and the current limited to 1 A. 
Membranes were washed and blocked with blocking buffer (5% wt/vol milk powder, 25 mM Tris/HCl pH 
7.4, 135 mM NaCl, 3 mM KCl, 0.02% IGEPAL).
As previously described, the anti-Kir6.2 antibody (raised in guinea pig and yielded as serum of  the 
third bleeding; ref. 51) recognizes the last 36 amino acids of  the protein and was characterized on native 
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tissue against Kir6.2-knockout controls (28). Information about antibodies against proteins other than 
Kir6.2 is shown in Table 1. Primary antibodies were diluted in blocking buffer and incubated overnight 
at 4°C. For antibodies against SUR proteins, a different blocking buffer (“SUR-blocking buffer”: 4% 
wt/vol milk powder, 25 mM Tris/HCl pH 7.4, 135 mM NaCl, 3 mM KCl, 0.1% Tween-20) was used. 
Subsequently, membranes were washed 3 times with their respective blocking buffer and incubated with 
IRDye LI-COR secondary antibodies (800CW) diluted in blocking buffer at 1:4000. Blots were incubat-
ed for 90 minutes at room temperature and washed with washing buffer (25 mM Tris/HCl pH 7.4, 135 
mM NaCl, 3 mM KCl, 0.1% Tween-20 for SUR proteins, 5% wt/vol milk powder, 25 mM Tris/HCl 
pH 7.4, 135 mM NaCl, 3 mM KCl, 0.02% IGEPAL for others), and antibody signals were subsequently 
visualized using an Odyssey Sa Infrared imaging system.
Patch clamp electrophysiology
Isolated VSMCs. Mice were anesthetized with 2.5% avertin (10 mL/kg, i.p.; MilliporeSigma), and the ascend-
ing aorta was rapidly dissected and placed in ice-cold physiological saline solution (PSS) containing (in mM): 
NaCl 134, KCl 6, CaCl2 2, MgCl2 1, HEPES 10, and glucose 10, with pH adjusted to 7.4 with NaOH. Smooth 
muscle cells were enzymatically dissociated in dissociation solution containing (in mM): NaCl 55, sodium 
glutamate 80, KCl 5.6, MgCl2 2, HEPES 10, and glucose 10, pH 7.3 with NaOH, then placed into dissociation 
solution containing papain 12.5 μg/mL, DTT 1 mg/mL, and BSA 1 mg/mL for 25 minutes (at 37°C), before 
immediate transfer to dissociation solution containing collagenase (type H:F = 1:2) 1 mg/mL and BSA 1 mg/
mL for 5 minutes (at 37°C). Cells were dispersed by gentle trituration using a Pasteur pipette, plated onto glass 
coverslips on ice and allowed to adhere for more than 1 hour before transfer to the recording chamber.
Whole-cell KATP currents were recorded using an Axopatch 200B amplifier and Digidata 1200 (Molecular 
Devices). Recordings were sampled at 3 kHz and filtered at 1 KHz. Currents were initially measured at a holding 
potential of –70mV in high-Na+ bath solution containing (in mM): NaCl 136, KCl 6, CaCl2 2, MgCl2 1, HEPES 
10, and glucose 10, with pH adjusted to 7.4 with NaOH before switching to a high-K+ bath solution (KCl 140, 
CaCl2 2, MgCl2 1, HEPES 10, and glucose 10, with pH adjusted to 7.4 with KOH) in the absence and presence 
of pinacidil and glibenclamide as indicated. The pipette solution contained (in mM) potassium aspartate 110, 
KCl 30, NaCl 10, MgCl2 1, HEPES 10, CaCl2 0.5, K2HPO4 4, and EGTA 5, with pH adjusted to 7.2 with KOH.
Isolated ventricular myocytes. Ventricular myocytes were isolated from adult mice, anesthetized using 2.5% 
Avertin (10 mL/kg), and the heart and ascending aorta were removed and immersed in ice-cold calcium 
free Wittenberg isolation medium (WIM; in mM): 116 NaCl, 5.4 KCl, 8 MgCl2, 1 NaH2PO4, 1.5 KH2PO4, 
4 NaHCO3, 12 glucose, 21 HEPES, 2 glutamine plus essential vitamins (Gibco) and essential amino acids 
(Gibco) (pH 7.40). The heart was cannulated via the aorta and Langendorff  perfused with WIM for 5 min-
utes at 37°C, followed by 20 minutes of  perfusion with WIM supplemented with 270 U/ml collagenase 
type 2 (Worthington Biochemical Corp.) and 10 μM CaCl2 at 37°C. The heart was then transferred to WIM 
containing 50 mg/mL BSA, 12.5 mg/mL taurine, and 150 μM CaCl2; and ventricular tissue was manually 
dissociated using forceps before single-cell dissociation by trituration with a fire-polished Pasteur pipette.
Inside-out patch clamp recordings were made in symmetrical KINT solution which contained (in mM): 
140 KCl, 10 HEPES, 1 EGTA (pH 7.4 with KOH). Varying MgATP concentrations were applied using a Dyna-
flow Resolve perfusion chip (Cellectricon). MgCl2 was added to each solution to achieve a free [Mg
2+] 0.5 mM 
Table 1. Antibody list
Antigen Clone/name Species Source Catalog no. Lot no. Concentration Dilution  (Western blot)





sc-21712 C0713 200 μg/mL 1:2000
SUR1 N289/16 Mouse Neuromab
75-267 4492AK44 1.03 mg/mL 1:500
73-267 #4375VA10 26.9 μg/mL 1:25
SUR2A N319A/14 Mouse Neuromab 73-296 4376VA13 22 μg/mL 1:15
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according to calculations using CaBuf (Katholieke Universiteit Leuven). Membrane currents were sampled at 
3 KHz and filtered at 1 KHz at a holding potential of –50 mV using an Axopatch 700B amplifier and Digidata 
1200 (Molecular Devices). KATP channel currents in solutions of varying nucleotide concentrations were normal-
ized to the basal current in the absence of nucleotides, and dose-response data were fit with a 4-parameter Hill 
fit according to the following equation: Normalized current = I + (Imax – Imin)/(1 + ([X]/IC50)
H); where the current 
in Kint = Imax = 1, Imin is the normalized minimum current observed in MgATP, [X] refers to the concentration of  
MgATP, IC50 is the concentration of half-maximal inhibition, and H denotes the Hill coefficient.
Whole-cell patch clamp recordings of  voltage-gated calcium channel activity were made in a bath 
solution that contained (in mM): 116 NaCl, 5.4 CsCl, 0.16 NaH2PO4, 10 glucose, 1.8 CaCl2, 0.5 MgCl2, 
5 HEPES, 3 NaHCO3, and 0.01 tetrodotoxin (pH 7.4 with NaOH) using a pipette solution that contained 
(in mM): 120 CsCl, 20 TEA-Cl, 5 K2ATP, and 10 HEPES (pH 7.3 with KOH). Cell capacitance and series 
resistance were determined from 5 mV square pulses from a holding potential of  –70 mV following estab-
lishment of  the whole-cell configuration. All recordings were performed at 20°C–22°C.
Arterial compliance
After mice were euthanized under isoflurane anesthesia, the ascending aorta and left common carotid 
artery of  3-week-old mice were excised and placed in a PSS containing 130 mM NaCl, 4.7 mM KCl, 1.18 
mM MgSO4-7H2O, 1.17 mM KH2PO4, 14.8 mM NaHCO3, 5.5 mM dextrose, and 0.026 mM EDTA (pH 
7.4). The vessels were then cleaned from surrounding fat, mounted on a pressure arteriograph (Danish 
Myo Technology), and maintained in PSS at 37°C. Vessels were visualized with an inverted microscope 
connected to a charge-coupled device camera and a computerized system, which allowed continuous 
recording of  vessel diameter. Intravascular pressure was increased from 0 to 175 mmHg by 25 mmHg 
increments, and the vessel outer diameter was recorded at each step (12 seconds per step). The average of  
3 measurements at each pressure was reported.
BP measurement
In anesthetized mice. Mice were anesthetized with 1.5% inhaled isoflurane and restrained on a heating pad to 
maintain body temperature. A 2- to 3-mm incision was made in the midline of the neck; the thymus and muscle 
were separated to expose the right carotid artery. A Millar pressure transducer (model SPR-671) was inserted 
into the right carotid artery and moved to the ascending aorta. Systolic BP (SBP), diastolic BP (DBP), and HR 
were recorded using the PowerLab data acquisition system (ADInstruments), and data were analyzed using 
LabChart 7 (ADInstruments). For blood pressure measurements in conscious mice, a radio-telemetry pressure 
transmitter (DSI) was surgically inserted into the left carotid artery and moved to the ascending aorta, where 
BPs during day and night were recorded by the DSI data acquisition system after mice recovered from surgery.
Telemetry probe implantation and telemetry recording. Mice (6–8 months old) were implanted with 
TA11PA-C10 (DSI) telemetric implants under anesthesia, with a gas concentration of  1.5%–2.5% isoflu-
rane. The catheter was advanced into the ascending aorta via the left carotid artery, and the body of  trans-
mitter was slipped into the pocket subcutaneously in the right flank. Animals were housed in an isolated 
recording room and allowed at least 1 week of  recovery before recordings were taken. Systolic (SBP), 
diastolic (DBP), mean arterial pressure (MBP = DBP + 1/3[SBP — DBP]), and HR were collected using 
the Dataquest ART system. Data were sampled by averaging 10 seconds of  each 1-minute period. Values of  
day and night were averages of  day time (6 am–6 pm) or night time (6 pm–6 am). After 3 days of  baseline 
recording, the mice were injected with pinacidil (i.p. 0.01, 0.1, 1 mg) daily.
Heart weight measurement and histology
Mice were anesthetized with 2.5 % Avertin, and hearts were excised and rinsed with PBS, which contained 
(in mM): 137 NaCl, 2.7 KCl, 10 Na2HPO4, KH2PO4 (pH 7.4 with NaOH). The hearts were arrested in 
diastole with 10% KCl and blotted to remove excess liquid. Hearts were then weighed, and weight was 
normalized to tibia length. After weighing, the hearts were fixed in 10% buffered formalin for 24 hours 
and embedded in paraffin. Sections (3 μm) were cut and stained with H&E for the morphometric analysis.
Echocardiography
Short-axis left ventricular scans were obtained via M-mode echocardiography using an ATL 5000cv instru-
ment (Phillips) with a 15-MHz compact linear array. The operator was blinded to genotype. Left ventricular 
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end-diastolic dimension (LVEDD), LV end-systolic dimension (LVESD), end diastolic anterior wall thickness 
(AWT), end diastolic posterior wall thickness (PWT), R-R interval, and ejection time (ET) were recorded 
from 3 separate cardiac cycles for each mouse. Wall thickness divided by chamber radius was calculated at 
diastole. LV mass (LVM) was calculated using the Devereux equation. Fractional shortening (FS%) refers to 
(LVEDD – LVESD)/LVEDD as a percentage. Stroke volume (SV) refers to the amount of  blood ejected by 
the left ventricle in one contraction, determined by subtracting LV end-systolic volume from LV end-diastolic 
volume (LVEDV – LVESV), assuming LVEDV and LVESV are simply cubed. The ejection fraction (EF%; 
SV/LVEDV) refers to the percentage of  blood that is pumped out of  the ventricles with each contraction.
Statistics
Unless otherwise noted, all data are presented as mean ± SEM and were tested for statistical significance 
using 1-way ANOVA, with post hoc Tukey’s test or 2-tailed Student’s t test as indicated. P values less than 
0.05 were considered statistically significant.
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